Is RenovoRx Inc (RNXT) overvalued? · rev $266.0K
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
This page asks whether RenovoRx Inc (RNXT) looks expensive on cached numbers — not a short thesis.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
RNXT currently screens at market cap $47.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RNXT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RNXT stock page for the full model, not this heading.
Not investment advice.